Head-to-head evidence
Azvudine vs Elsulfavirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Azvudine · FNC
Marketed by Henan Genuine Biotech
NCT04303598 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial testing whether azvudine achieves viral suppression as well as an established comparator, using a recognized clinical measure of HIV control, but results are not yet posted so the outcome is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Elsulfavirine · Elpida
Marketed by Viriom
NCT02489461 · Phase 2/3 · completed
The study randomized 150 participants and used double blinding with an active efavirenz comparator. Its primary endpoint was the proportion with HIV-1 RNA below 400 copies/mL at Week 12, but no results are posted, so the outcome comparison cannot be assessed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Azvudine's landscape · Elsulfavirine's landscape